Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yoshihisa Matsukawa, Yoshie Kanada, Shun Takai, Satoshi Inoue, Tsuyoshi Majima, Yasuhito Funahashi, Masashi Kato, Tokunori Yamamoto & Momokazu Gotoh. (2020) Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction. The Aging Male 23:5, pages 641-647.
Read now
Read now
Naoya Masumori, Taiji Tsukamoto, Akihiko Shibuya, Noriomi Miyao, Yasuharu Kunishima & Akihiko Iwasawa. (2016) Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan. Patient Preference and Adherence 10, pages 1309-1316.
Read now
Read now
Fabio Castiglione, Fabio Benigni, Alberto Briganti, Andrea Salonia, Luca Villa, Alessandro Nini, Ettore Di Trapani, Umberto Capitanio, Petter Hedlund & Francesco Montorsi. (2014) Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion 30:4, pages 719-732.
Read now
Read now
Naoya Masumori. (2011) Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Therapeutics and Clinical Risk Management 7, pages 227-238.
Read now
Read now
Articles from other publishers (24)
Henk van der Worp, Boudewijn J. Kollen, Tom Vermist, Martijn G. Steffens & Marco H. Blanker. (2019) Symptom improvement and predictors associated with improvement after 6 weeks of alpha-blocker therapy: An exploratory, single-arm, open-label cohort study. PLOS ONE 14:7, pages e0220417.
Crossref
Crossref
Koji Ichihara, Naoya Masumori, Akihiko Iwasawa, Keisuke Taguchi, Yasuhiro Yamaguchi, Masahiro Nishimura, Hiroto Sasamura, Nobukazu Suzuki, Kazunori Haga, Noriomi Miyao & Takaoki Hirose. (2018) Silodosin as second‐line α‐blocker monotherapy in patients with benign prostatic hyperplasia: A prospective observational study. International Journal of Urology 25:10, pages 849-854.
Crossref
Crossref
Yoshihisa Matsukawa, Shun Takai, Tsuyoshi Majima, Yasuhito Funahashi, Masashi Kato, Tokunori Yamamoto & Momokazu Gotoh. (2018) Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics. Therapeutic Advances in Urology 10:9, pages 263-272.
Crossref
Crossref
Kaoru Nemoto, Yasutomo Suzuki & Yukihiro Kondo. (2018) Current work environments: What problems are being faced by Japanese urologists?. International Journal of Urology 25:4, pages 327-336.
Crossref
Crossref
Amy Y. Zhang & Xinyi Xu. (2018) Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature. SAGE Open Nursing 4, pages 237796081881177.
Crossref
Crossref
Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi, Tsuyoshi Majima, Masashi Kato, Tokunori Yamamoto & Momokazu Gotoh. (2017) Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. Journal of Urology 198:4, pages 905-912.
Crossref
Crossref
Yoshihisa Matsukawa, Masashi Kato, Yasuhito Funahashi, Tsuyoshi Majima, Tokunori Yamamoto & Momokazu Gotoh. (2017) What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study. Neurourology and Urodynamics 36:7, pages 1809-1815.
Crossref
Crossref
Yoshihisa Matsukawa, Shohei Ishida, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Masashi Kato, Yasushi Yoshino & Momokazu Gotoh. (2017) Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms. International Journal of Urology 24:6, pages 454-459.
Crossref
Crossref
Simone Albisinni, Ibrahim Biaou, Quentin Marcelis, Fouad Aoun, Cosimo De Nunzio & Thierry Roumeguère. (2016) New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives. BMC Urology 16:1.
Crossref
Crossref
Tomonori Yamanishi, Kanya Kaga, Miki Fuse, Chiharu Shibata, Takao Kamai & Tomoyuki Uchiyama. (2015) Six‐year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?. International Journal of Urology 22:12, pages 1143-1148.
Crossref
Crossref
C. Füllhase, M. Hennenberg, P. Sandner, F. Strittmatter, C. Niedworok, R.M. Bauer, C. Gratzke, R. Soler, C. Stief & K.E. Andersson. (2015) Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. Neurourology and Urodynamics 34:8, pages 787-793.
Crossref
Crossref
Naoya MASUMORI, Taiji TSUKAMOTO, Hiroki HORITA, Ken‐ichi SUNAOSHI, Yoshinori TANAKA, Koh TAKEYAMA, Eiji SATO & Noriomi MIYAO. (2013) Does Baseline Prostate Volume Affect the Short‐Term Outcome of Tamsulosin?. LUTS: Lower Urinary Tract Symptoms 6:2, pages 113-116.
Crossref
Crossref
Naoya Masumori, Taiji Tsukamoto, Hiroki Horita, Ken‐ichi Sunaoshi, Yoshinori Tanaka, Koh Takeyama, Eiji Sato & Noriomi Miyao. (2012) α1‐blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5‐year outcome analysis of a prospective multicenter study. International Journal of Urology 20:4, pages 421-428.
Crossref
Crossref
Iqbal Singh, Ankit Gupta, Vivek Agrawal & Mohit Joshi. (2013) A Randomized Clinical Study to Compare the Efficacy and Safety of Naftopidil Versus Tamsulosin in Symptomatic Benign Prostatic Hyperplasia. UroToday International Journal 06:02.
Crossref
Crossref
Yukio Homma, Momokazu Gotoh, Osamu Yokoyama, Naoya Masumori, Akihiro Kawauchi, Tomonori Yamanishi, Osamu Ishizuka, Narihito Seki, Toshiyuki Kamoto, Atsushi Nagai & Seiichiro Ozono. (2011) JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology 18:11.
Crossref
Crossref
Yukio Homma, Momokazu Gotoh, Osamu Yokoyama, Naoya Masumori, Akihiro Kawauchi, Tomonori Yamanishi, Osamu Ishizuka, Narihito Seki, Toshiyuki Kamoto, Atsushi Nagai & Seiichiro Ozono. (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology 18:11, pages 741-756.
Crossref
Crossref
Naoya Masumori, Fumimasa Fukuta & Taiji Tsukamoto. (2011) Natural history of benign prostatic hyperplasia. Journal of Men's Health 8:S1, pages S19-S21.
Crossref
Crossref
Yasuhito Funahashi, Ryohei Hattori, Yoshihisa Matsukawa, Tomonori Komatsu, Naoto Sassa & Momokazu Gotoh. (2010) Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia. World Journal of Urology 29:2, pages 225-231.
Crossref
Crossref
Tetsuya Imamura, Kenichiro Ishii, Hideki Kanda, Shigeki Arase, Yuko Yoshio, Yasuhide Hori, Norihito Soga, Hideaki Kise, Kiminobu Arima & Yoshiki Sugimura. (2009) Structural changes in α1-adrenoceptor antagonist-treated human prostatic stroma. Clinical and Experimental Medicine 10:2, pages 99-106.
Crossref
Crossref
Ryoji Furuya, Naoya Masumori, Seiji Furuya, Hiroshi Ogura, Masatoshi Mutoh, Ko Kobayashi, Shin-ichi Hisasue & Taiji Tsukamoto. (2010) INVESTIGATION OF ADVERSE EVENTS AND THE CONTINUANCE RATE OF SILODOSIN IN ALL PATIENTS WHO RECEIVED SILODOSIN FOR LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA. The Japanese Journal of Urology 101:1, pages 13-17.
Crossref
Crossref
Pranav S. Garimella, Howard A Fink, Roderick MacDonald & Timothy J Wilt. (2009) Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Motoi Takeuchi, Naoya Masumori & Taiji Tsukamoto. (2009) Contemporary Patients With LUTS/BPH Requiring Prostatectomy Have Long-term History of Treatment With α1-Blockers and Large Prostates Compared With Past Cases. Urology 74:3, pages 606-609.
Crossref
Crossref
Debra A Schwinn & Claus G Roehrborn. (2008)
α
1
‐Adrenoceptor subtypes and lower urinary tract symptoms
. International Journal of Urology 15:3, pages 193-199.
Crossref
Crossref
Taiji Tsukamoto & Naoya Masumori. (2008) Prostatic diseases in elderly men: Contemporary diagnosis and treatment of cancer and benign hyperplasia of the prostate. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 45:2, pages 135-137.
Crossref
Crossref